Evidence map›Paper›PMID 31611281›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2019

A New Pathway Emerges to Interpret Lung Cancer Genomic Alterations.

Collin M Blakely

Abstract readComment
PubMed Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 88% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Collin M BlakelyDepartment of Medicine, University of California, San Francisco, California. collin.blakely@ucsf.edu.
University of California, San Francisco · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The clinical utility of performing tumor genetic testing to assess for alterations beyond the known targetable oncogenes in lung adenocarcinoma is unclear. Analyzing cancer pathway alterations beyond single oncogenic driver mutations in addition to markers of tumor mutation burden and genomic instability may provide additional predictive and prognostic information.

Indexed as

Adenocarcinoma of LungLung NeoplasmsGenomicsHigh-Throughput Nucleotide SequencingHumansMutation

Identifiers

PMID31611281
OpenAlexW2979890064

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.